New Data from Fudan University Illuminate Findings in Thyroid Cancer (Targeting Cdk2 Confers Vulnerability To Lenvatinib Via Driving Senescence In Anaplastic Thyroid Cancer).

A study conducted at Fudan University in Shanghai, China, focused on anaplastic thyroid cancer (ATC) and the use of lenvatinib as a treatment option. The research found that targeting Cdk2 in combination with lenvatinib could be effective in treating lenvatinib-resistant ATC patients with high CDK2 expression. The study highlights the potential of a combination therapy strategy for improving clinical outcomes in ATC patients. The findings were published in Advanced Science and can be accessed online. [Extracted from the article]